GenScript Wins Top Innovation & Collaborations in ADC Drug Development at BioSpectrum Asia Excellence Awards Ceremony

December 12, 2024

[Singapore, 12^th December 2024] – GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, proudly announced that it has received the prestigious Top Innovation & Collaborations in ADC Drug Development award at the BioSpectrum Asia Excellence Awards Ceremony. This accolade highlights GenScript’s contributions to the field of antibody-drug conjugates (ADCs), transforming targeted cancer therapies.

Central to this recognition is GenScript's proprietary TurboCHO™ Antibody Expression Platform. Antibody-drug conjugates represent a rapidly growing sector in oncology, offering highly targeted treatments with minimized off-target effects. GenScript's TurboCHO™ platform addresses fundamental antibody part challenges in ADC development, from scalability to precision, providing substantial advancements that have transformed the landscape of targeted therapies.

The platform’s unparalleled efficiency accelerates the production of antibodies, featuring the market's fastest turnaround time—just 5 business days from gene to antibody. With a large capacity of 30,000+ targets/month, TurboCHO™ ensures a seamless production with scalable production up to gram level.

Leveraging automated high-throughput systems and integrated AI capabilities, GenScript has revolutionized the development pipeline for antibody expression for ADCs. These innovations ensure precise antibody production, significantly reducing development timelines and costs, thus ensuring patients receive timely and affordable therapeutics treatment.

“This award reflects our commitment to driving innovation and enabling breakthroughs in therapeutic drug development,” said Dr. Janice Jin, President of GenScript Asia Pacific. “The TurboCHO™ platform is a testament to our dedication to delivering industry-leading solutions that empower biopharma companies and enhance patient care worldwide.”

About GenScript Biotech Corporation

GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript ’s services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world.

For more information, please visit GenScript Biotech's official website.